Lupin has launched generic Lanthanum Carbonate chewable tablets which is used in reducing serum phosphate in patients with end stage kidney disease in the American market.
It said in a statement that the company has launched Lanthanum Carbonate chewable tablets 500 mg (base), 750 mg (base) and 1000 mg (base) after its partner Natco received an approval from the United States Food and Drug Administration (USFDA) for them.
It added that Natco’s tablets are generic version of Shire Development LLC’s Fosrenol chewable tablets in the same strengths.
